Cyclacel Pharmaceuticals Announces Multiple Abstracts Selected for Presentation at American Association for Cancer Research Annual Meeting Translational Studies Highlight Unique Mechanism of Action and New Potential Clinical Applications for Sapacitabine and Seliciclib http://finance.yahoo.com/news/Cyclacel-Pharmaceuticals-pz-3996680954.html?x=0&.v =1Posts: 2383 | Registered: Apr 2006
| IP: Logged |
Peregrine Announces Data From Four Clinical Studies Will Be Presented at 2010 ASCO Annual Meeting Will Include Data From Bavituximab Breast and Non-Small Cell Lung Cancer Phase II Studies and Cotara Brain Cancer Study
Delcath Systems, Inc.(NasdaqCM: DCTH) Real-Time: 10.53 0.64 (6.47%) 4:00pm ET
Last Trade: 10.59 Trade Time: 3:55PM ET Change: 0.70 (7.08%) Prev Close: 9.89 Open: 10.00 Bid: 10.61 x 400 Ask: 10.62 x 2400 1y Target Est: 8.17 Day's Range: 9.94 - 10.74 52wk Range: 2.09 - 10.74 Volume: 1,894,171 Avg Vol (3m): 862,864 Market Cap: 384.53M P/E (ttm): N/A EPS (ttm): -0.82 Div & Yield: N/A (N/A
$14.60 going in PM...
Delcath Phase III Trial Results Exceed Primary Endpoint Expectations Treatment Arm Shows More Than 3x Median hPFS Compared to Control Arm Conference Call Today at 5:15 p.m. ET
Cyclacel Pharmaceuticals Announces Multiple Abstracts Selected for Presentation at American Association for Cancer Research Annual Meeting Translational Studies Highlight Unique Mechanism of Action and New Potential Clinical Applications for Sapacitabine and Seliciclib http://finance.yahoo.com/news/Cyclacel-Pharmaceuticals-pz-3996680954.html?x=0&.v =1
Added to the stash $2.31...
Posts: 2383 | Registered: Apr 2006
| IP: Logged |